(Q38261370)

1 September 2017

1 reference

title

Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention (English)

1 reference

1 September 2017

Alastair J Barr

3

0 references

Michael Overduin

object named as

Michael Overduin

series ordinal

2

0 references

author name string

Sam Butterworth

series ordinal

1

1 reference

1 September 2017

1 August 2014

1 reference

Future Medicinal Chemistry

1 September 2017

1 reference

1 September 2017

6

1 reference

1 September 2017

12

1 reference

1 September 2017

1423-1437

1 reference

Tyrosine phosphorylation: thirty years and counting

1 September 2017

1 reference

Nonreceptor protein-tyrosine phosphatases in immune cell signaling

21 January 2018

1 reference

Receptor and nonreceptor protein tyrosine phosphatases in the nervous system

21 January 2018

1 reference

Protein tyrosine phosphatases: from genes, to function, to disease

21 January 2018

1 reference

Protein tyrosine phosphatases in the human genome

21 January 2018

1 reference

Structural and evolutionary relationships among protein tyrosine phosphatase domains

21 January 2018

1 reference

Protein tyrosine phosphatases: structure, function, and implication in human disease.

21 January 2018

1 reference

Serine/threonine phosphatases: mechanism through structure

21 January 2018

1 reference

The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling

21 January 2018

1 reference

PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase

21 January 2018

1 reference

A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map, but not c-Jun amino-terminal kinase activation.

21 January 2018

1 reference

Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation

21 January 2018

1 reference

Crystal structure of the tyrosine phosphatase SHP-2

21 January 2018

1 reference

Large-scale structural analysis of the classical human protein tyrosine phosphatome

21 January 2018

1 reference

Structural basis for substrate specificity of protein-tyrosine phosphatase SHP-1

21 January 2018

1 reference

The "Gab" in signal transduction.

21 January 2018

1 reference

Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis

21 January 2018

1 reference

Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling

21 January 2018

1 reference

Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling

21 January 2018

1 reference

Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.

21 January 2018

1 reference

Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2.

21 January 2018

1 reference

Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice

21 January 2018

1 reference

Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function

21 January 2018

1 reference

SH2 domain-containing phosphatase 2 is a critical regulator of connective tissue mast cell survival and homeostasis in mice

21 January 2018

1 reference

Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection

21 January 2018

1 reference

Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality

21 January 2018

1 reference

Shp2 controls female body weight and energy balance by integrating leptin and estrogen signals.

21 January 2018

1 reference

Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways

21 January 2018

1 reference

Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation

21 January 2018

1 reference

Targeted disruption of Shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions

21 January 2018

1 reference

Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations

21 January 2018

1 reference

Conditional deletion of Shp2 tyrosine phosphatase in thymocytes suppresses both pre-TCR and TCR signals.

21 January 2018

1 reference

Coordinated regulation by Shp2 tyrosine phosphatase of signaling events controlling insulin biosynthesis in pancreatic beta-cells

21 January 2018

1 reference

Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis

21 January 2018

1 reference

Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis

21 January 2018

1 reference

Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.

21 January 2018

1 reference

Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis

21 January 2018

1 reference

Checks and balances: interplay of RTKs and PTPs in cancer progression

21 January 2018

1 reference

Protein tyrosine phosphatase function: the substrate perspective

21 January 2018

1 reference

Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor Signaling

21 January 2018

1 reference

Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates

21 January 2018

1 reference

A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation

21 January 2018

1 reference

Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment

21 January 2018

1 reference

The tyrosine phosphatase Shp2 (PTPN11) in cancer.

21 January 2018

1 reference

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

21 January 2018

1 reference

Noonan syndrome and related disorders: genetics and pathogenesis

21 January 2018

1 reference

Prevalence of priapism in children and adolescents with sickle cell anemia.

21 January 2018

1 reference

Biochemical and functional characterization of germ line KRAS mutations

21 January 2018

1 reference

21 January 2018

1 reference

Targeting SHP2 phosphatase in myeloproliferative neoplasms

21 January 2018

1 reference

Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes

21 January 2018

1 reference

Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells

21 January 2018

1 reference

PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects

21 January 2018

1 reference

Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 Mutations

21 January 2018

1 reference

Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)

21 January 2018

1 reference

Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis

21 January 2018

1 reference

Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.

21 January 2018

1 reference

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia

21 January 2018

1 reference

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

21 January 2018

1 reference

A role for the scaffolding adapter GAB2 in breast cancer

21 January 2018

1 reference

Focal amplification and oncogene dependency of GAB2 in breast cancer

21 January 2018

1 reference

SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis

21 January 2018

1 reference

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

21 January 2018

1 reference

Targeting protein-tyrosine phosphatases in breast cancer

21 January 2018

1 reference

Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis

21 January 2018

1 reference

Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome

21 January 2018

1 reference

Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene

21 January 2018

1 reference

Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors

21 January 2018

1 reference

Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors

21 January 2018

1 reference

The genetic landscape of high-risk neuroblastoma

21 January 2018

1 reference

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

21 January 2018

1 reference

The therapeutic potential of phosphatase inhibitors

21 January 2018

1 reference

Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer

21 January 2018

1 reference

Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development

21 January 2018

1 reference

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1

21 January 2018

1 reference

Selectivity and therapeutic inhibition of kinases: to be or not to be?

21 January 2018

1 reference

Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines

21 January 2018

1 reference

Discovery of a novel shp2 protein tyrosine phosphatase inhibitor

21 January 2018

1 reference

Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds

21 January 2018

1 reference

Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.

21 January 2018

1 reference

Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis

21 January 2018

1 reference

Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.

21 January 2018

1 reference

Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)

21 January 2018

1 reference

Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs

21 January 2018

1 reference

2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action

21 January 2018

1 reference

Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies

21 January 2018

1 reference

Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay

21 January 2018

1 reference

Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).

21 January 2018

1 reference

Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents

21 January 2018

1 reference

SHP2 is a target of the immunosuppressant tautomycetin

21 January 2018

1 reference

GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis

21 January 2018

1 reference

A Potent and Selective Small-Molecule Inhibitor for the Lymphoid-Specific Tyrosine Phosphatase (LYP), a Target Associated with Autoimmune Diseases

21 January 2018

1 reference

Pentavalent antimonials: new perspectives for old drugs

21 January 2018

1 reference

Anticancer activity of sodium stibogluconate in synergy with IFNs

21 January 2018

1 reference

NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26).

21 January 2018

1 reference

Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice

21 January 2018

1 reference

New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling

21 January 2018

1 reference

Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma

21 January 2018

1 reference

The use of estramustine phosphate in the modern management of advanced prostate cancer

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of estramustine phosphate

21 January 2018

1 reference

Targeting the disordered C terminus of PTP1B with an allosteric inhibitor

21 January 2018

1 reference

Catalytic inactivation of protein tyrosine phosphatase CD45 and protein tyrosine phosphatase 1B by polyaromatic quinones

21 January 2018

1 reference

Tautomycetin is a novel and specific inhibitor of serine/threonine protein phosphatase type 1, PP1.

21 January 2018

1 reference

Tautomycetin as a novel immunosuppressant in transplantation

21 January 2018

1 reference

Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction

21 January 2018

1 reference

Tautomycetin inhibits growth of colorectal cancer cells through p21cip/WAF1 induction via the extracellular signal-regulated kinase pathway

21 January 2018

1 reference

Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells

21 January 2018

1 reference

Differential effects of tautomycetin and its derivatives on protein phosphatase inhibition, immunosuppressive function and antitumor activity

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.14.88

1 reference

1 September 2017

1 reference

PubMed ID

25329198